Lexicon Pharmaceuticals’ (LXRX) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note published on Friday,Benzinga reports.

LXRX has been the subject of several other reports. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. Leerink Partners set a $6.00 price objective on Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a research note on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $6.00.

Lexicon Pharmaceuticals Stock Performance

Shares of NASDAQ LXRX opened at $0.86 on Friday. The firm’s 50-day moving average price is $1.53 and its 200-day moving average price is $1.70. Lexicon Pharmaceuticals has a 52-week low of $0.73 and a 52-week high of $3.73. The company has a market cap of $212.60 million, a PE ratio of -1.15 and a beta of 1.24. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). The company had revenue of $1.75 million during the quarter, compared to the consensus estimate of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. During the same period last year, the firm posted ($0.21) EPS. As a group, analysts anticipate that Lexicon Pharmaceuticals will post -0.69 EPS for the current year.

Institutional Trading of Lexicon Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. CVI Holdings LLC bought a new position in Lexicon Pharmaceuticals in the 2nd quarter worth approximately $34,000. Principal Financial Group Inc. lifted its position in shares of Lexicon Pharmaceuticals by 116.1% in the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 12,225 shares in the last quarter. Great Point Partners LLC purchased a new position in Lexicon Pharmaceuticals during the 2nd quarter valued at approximately $50,000. BNP Paribas Financial Markets raised its holdings in shares of Lexicon Pharmaceuticals by 71.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 13,246 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Lexicon Pharmaceuticals by 107.6% in the third quarter. SG Americas Securities LLC now owns 46,090 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 23,893 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.